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Abstract
Inflammation affects the formation and the progression of various vitreoretinal diseases. We performed a comprehensive
analysis of inflammatory immune mediators in the vitreous fluids from total of 345 patients with diabetic macular edema
(DME, n=92), proliferative diabetic retinopathy (PDR, n=147), branch retinal vein occlusion (BRVO, n=30), central retinal
vein occlusion (CRVO, n=13) and rhegmatogenous retinal detachment (RRD, n=63). As a control, we selected a total of 83
patients with either idiopathic macular hole (MH) or idiopathic epiretinal membrane (ERM) that were free of major
pathogenic intraocular changes, such as ischemic retina and proliferative membranes. The concentrations of 20 soluble
factors (nine cytokines, six chemokines, and five growth factors) were measured simultaneously by multiplex bead analysis
system. Out of 20 soluble factors, three factors: interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemoattractant
protein-1 (MCP-1) were significantly elevated in all groups of vitreoretinal diseases (DME, PDR, BRVO, CRVO, and RRD)
compared with control group. According to the correlation analysis in the individual patient’s level, these three factors that
were simultaneously increased, did not show any independent upregulation in all the examined diseases. Vascular
endothelial growth factor (VEGF) was significantly elevated in patients with PDR and CRVO. In PDR patients, the elevation of
VEGF was significantly correlated with the three factors: IL-6, IL-8, and MCP-1, while no significant correlation was observed
in CRVO patients. In conclusion, multiplex bead system enabled a comprehensive soluble factor analysis in vitreous fluid
derived from variety of patients. Major three factors: IL-6, IL-8, and MCP-1 were strongly correlated with each other
indicating a common pathway involved in inflammation process in vitreoretinal diseases.
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Introduction
Vitreoretinal diseases, such as diabetic retinopathy (DR), retinal
vein occlusion (RVO), and retinal detachment (RD) have a poor
visual prognosis. Although these diseases have variety of etiology,
their pathogenic retinal changes (including angiogenesis and
fibrosis) cause local inflammation. In fact, infiltration of leukocytes
into the choroid, retina, and vitreous is observed in various
vitreoretinal disorders, including PDR [1], proliferative vitreor-
etinopathy (PVR) [2], as well as in obvious inflammatory ocular
diseases such as endophthalmitis and uveitis. Even though such
leukocyte infiltration may be only a secondary event, it damages
retinal tissues.
During inflammation a variety of soluble factors are secreted
into the vitreous cavity (posterior chamber of the eye) and their
concentrations may reflect visual prognosis. Cytokines, which
usually serve as signals between neighboring cells, are involved in
essentially every important biological process, including cell
proliferation, inflammation, immunity, migration, fibrosis, tissue
repair, and angiogenesis [3,4]. Chemokines are multifunctional
mediators that can direct the recruitment of leukocytes to sites of
inflammation, promote the process, enhance immune responses,
and promote stem cell survival, development, and homeostasis [5].
Recently, it has been demonstrated that chemokines play a pivotal
role in mediating angiogenesis and fibrosis as well [6,7].
DR is one of the most severe complication of diabetes mellitus
and a leading cause of blindness. DR can further be divided into
non-proliferative diabetic retinopathy (NPDR) and PDR. NPDR
causes central vision loss when it induces DME. PDR is the most
advanced stage of DR, which is characterized by retinal
neovasculization. The pathology of PDR includes vitreous
hemorrhage, formation of fibrous peri-retinal tissue comprising
neovascular blood vessels, tractional retinal detachment and total
vision loss as the final stage. Various mechanisms play a role in
the pathogenesis of DR, including the disruption of blood-
retinal barrier, alterations to capillary vessel walls, synthesis of
growth factors and nitric oxide, disruption of connective tissue by
matrix metalloproteinases, and activation of various immune
mechanisms.
RVO is another common retinal vascular disorder and a
common cause of visual impairment. Between the two types of
RVO, BRVO is more common than CRVO. The pathogenesis of
CRVO is multifactorial while BRVO is believed to be driven by a
combination of three primary mechanisms: compression of the
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vessel wall, and abnormal hematological factors [8].
RRD is defined as the separation of the neurosensory retina
from subjacent retinal pigment epithelium (RPE) caused by
penetration of fluids into the subretinal space via one or more
full-thickness retinal breaks. Initial detachment may be local, but
without rapid treatment the entire retina may detach, which may
lead to vision loss and blindness. Lewandowska-Furmanik et al.
suggested the involvement of the immune system in pathogenesis
of RRD following the detection of some cytokine concentrations in
subretinal fluid of 36 RRD patients [9].
Aiello et al. reported VEGF was detected from ocular fluid with
diabetic retinopathy and other retinal disorders [10]: there are
other reports measuring multiple soluble factors in samples from
different vitreoretinal disorders using conventional enzyme-linked
immunosorbent assay (ELISA) [11-16]. However, the examination
of complex patterns of these factors in human vitreoretinal diseases
has been limited by the small number of vitreous samples available
from each patient. Recently, a particle-based flow cytometric
analysis method has been established to improve the conventional
method and overcome many of these limitations [17]. Two recent
studies demonstrated the analysis of vitreous inflammatory
mediators by multiplex bead analysis in 58 patients with several
vitreoretinal disorders and 32 patients with diabetic patients
[18,19]. Djoba Siawaya and colleagues [20] compared between
the multiplex assays based on Luminex technology and established
ELISA technique. Their conclusion was that currently the most
appropriate use for the Luminex technology is as a screening tool.
In this study we report the use of Luminex technique for
analysis of complex network of immune mediators in vitreous
humor and the relations between them; we examined a profile of
immune mediators in 345 eyes from patients undergoing
vitrectomy. Moreover, the correlations between several immune
mediators related to different vitreoretinal diseases were deter-
mined. Finding patterns in expression of inflammatory cytokines
specific to a particular disease can substantially contribute to the
understanding of the basic mechanism of this disease and
consequently to the development of a targeted therapy.
Results
Detection of Soluble Factors in Vitreous Fluids from
Patients
The bibliography of enrolled patients was shown in Table 1.
The investigated inflammatory mediators were categorized into
three groups: (1) nine cytokines: IL-1b, IL-2, IL-4, IL-5, IL-6, IL-
10, IL-17, interferon-c (IFN-c), tumor necrosis factor-a (TNF-a)
(Table 2); (2) six chemokines: IL-8, eotaxin, MCP-1/CCL2,
macrophage inflammatory protein-1a (MIP-1a), MIP-1b, and
regulated on activation, normal T cell expressed and secreted
(RANTES)/CCL5 (Table 3); and (3) five growth factors:
epidermal growth factor (EGF), VEGF, basic FGF, granulocyte
colony-stimulating factor (G-CSF) and granulocyte-macrophage
colony-stimulating factor (GM-CSF) (Table 4). We found that four
out of twenty soluble factors: IL-6, IL-8, MCP-1, and VEGF were
predominantly detected in vitreous fluids from patients (Table 2-
4). In addition, MIP-1b, G-CSF, and GM-CSF were detected in
limited number of patients. For instance, we found one CRVO
patient with extremely high concentration of these four cytokines
(IL-6: 11103 pg/ml, IL-8: 6821 pg/ml, MCP-1: 15403 pg/ml,
VEGF: 11737 pg/ml) that showed extra high concentrations of G-
CSF (467.6 pg/ml) and GM-CSF (1036 pg/ml).
The concentrations of IL-1b, IL-2, IL-4, IL-5, IL-10, IL-17, IFN-
c,T N F - a, eotaxin, MIP-1a, RANTES, EGF and bFGF were under
the detection level in all the examined samples (the minimal
detectable concentration is listed in Table 2–4). Technical issues
were excluded as control recombinant proteins were detected (data
not shown). Moreover, concentrations of soluble factors (IFN-c,
TNF-a, and IL-2) in aqueous humor from acute uveitis patients
(somesampleswereactuallymeasured onthesameplate inthisstudy
series) were detected [21], in accordance with previous findings [22].
In addition extremely high concentrations of IL-10 were detected in
vitreous fluids from intraocular malignant lymphoma patients in
this system (data not shown), in support with previous findings [23].
IL-6, IL-8 and MCP-1 Were Increased in All Examined
Diseases, but VEGF Was Increased in PDR and CRVO
Patients Only
Since the four factors (IL-6, IL-8, MCP-1 and VEGF) could be
detected in the majority of the patients, we decided to further
study these factors. In Figure 1, every individual dot represents a
measured concentration which is plotted in log scale (y axis) and
bars represent the mean value of each group. Compared with
control subjects (either ERM or MH), the concentrations of IL-6
(Figure 1A), IL-8 (Figure 1B), and MCP-1 (Figure 1C) were
significantly higher in patients with DME, PDR, BRVO, CRVO,
and RRD. VEGF levels were significantly higher in samples from
patients with either PDR or CRVO than in control(Figure 1D),
but not in samples from DME nor BRVO despite the same
category of disease used (DR and RVO, respectively). RD patients
did not show any elevated levels of VEGF.
The concentrations of all four factors, IL-6, IL-8, MCP-1 and
VEGF, were significantly high within the same disease category,
Table 1. The bibliography of enrolled patients (age: mean6SD).
female male total
control n=57 (65.768.2) n=26 (67.866.8) n=83 (66.467.8)
DME n=46 (63.967.4) n=46 (62.469.7) n=92 (63.068.6) DME/PDR: p,0.00011
PDR n=43 (56.3613.6) n=104 (55.6612.1) n=147 (55.8612.5)
BRVO n=17 (70.0610.6) n=13 (69.2611.2) n=30 (69.7610.7) BRVO/CRVO: p=0.59691
CRVO n=7 (69.6611.0) n=6 (74.0611.1) n=13 (71.6610.8)
RRD n=28 (62.3612.0) n=35 (60.669.3) n=63 (61.4610.5)
P value p=0.0003* p,0.0001* p,0.0001*
*Kruskal-Wallis test,
1Mann-Whitney U test.
doi:10.1371/journal.pone.0008158.t001
Vitreoretinal Immunity
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these factors level were higher than in BRVO (Figure 1A–D).
IL-6, IL-8 and MCP-1 Are Mutually Increased in All
Analyzed Vitreoretinal Diseases
Since the three factors: IL-6, IL-8 and MCP-1 were commonly
upregulated in all the examined five diseases (DME, PDR, BRVO,
CRVO, and RRD), a Spearman’s correlation analysis was
performed between the three factors. In each disease, we analyzed
total of three combinations (two factors out of three), represented
in dots, and calculated p- and r-values which indicate the accuracy
of the correlation. An example is the correlation shown in DME
data where the dots are placed along with the median line, p-
values are less than 0.05, and r-values are high in all three
combinations (IL-6/IL-8, IL-6/MCP-1 and IL-8/MCP-1)
(Figure 2). This setting means that the three factors are correlated
with each other in DME patients. The results of p-values and r-
values are shown in Figure 3 (upper three lines). All three
combinations of IL-6/IL-8, IL-6/MCP-1 and IL-8/MCP-1 in the
studied groups showed significant correlations (p,0.05) except
from IL-8/MCP-1 in CRVO (Figure 3, upper three lines).
VEGF Independently Contribute to the Pathogenic
Process of PDR and CRVO
Since VEGF was significantly increased in PDR and CRVO
patients (Figure 1), the correlation between VEGF and the three
factors: IL-6, IL-8, and MCP-1 in PDR and CRVO were
investigated. Figure 3 shows the result of six combinations
including VEGF in PDR (Figure 4A) and CRVO (Figure 4B).
The p-values and r-values are summarized in Figure 3 (lower three
lines). In PDR patients, the elevation of VEGF was significantly
correlated with the other three factors, while no significant
correlation was observed in CRVO patients (Figure 3, lower three
lines). Unlike the three factors: IL-6, IL-8 and MCP-1, VEGF was
not a common factor, but may independently play a role in the
pathologic process in PDR and CRVO.
Serum IL-6 and VEGF Concentrations Are Not
Significantly Related with Vitreous Concentrations
Because vitreoretinal diseases examined in this study develop
neovasculization in the eye, it is likely to expect that mediators in
the circulation are easily and passively enter the vitreous.
Therefore, we decided to measure the proteins in serum in PDR
and CRVO groups as neovascularized eye diseases. Based on our
findings, we measured IL-6, as a representative inflammatory
marker, and VEGF concentrations in serum from control patients
and patients with highly angiogenic diseases using standard ELISA
technique. All serum samples we could have and vitreous samples
which correspond to each patient were statistically analyzed
(control: n=53, PDR: n=66, CRVO: n=8; Table 5 and
Figure 5). Even in the reduced numbers, we confirmed vitreous
IL-6/VEGF concentrations were significantly increased in PDR/
CRVO patients than control. However, serum IL-6/VEGF
concentrations were not increased in PDR/CRVO patients
(Figure 5). The data clearly indicate that vitreous soluble factors
are mainly from ocular tissues.
Discussion
Inflammatory processes have been considered to be critical in
vitreoretinal diseases [24-26]. The concentrations of inflammatory
soluble factors might not necessarily reflect a pathogenic process,
especially the microenvironments inside the retina. However,
secreted factors in the vitreous cavity appear to be associated with
pathological processes. Analyzing these factors can provide new
insights relating to the biological mechanism of the disease and to
Table 2. Concentrations of cytokines in the vitreous cavity.
IL-1b IL-2 IL-4 IL-5 IL-6 IL-10 IL-17 IFN-c TNF-a
Control ,150 ,60 ,50 ,30 12.1(,30–206.8) ,50 ,100 ,50 ,100
DME ,150 ,60 ,50 ,30 174(,30–1152) ,50 ,100 ,50 ,100
PDR ,150 ,60 ,50 ,30 330.1(,30–8630) ,50 ,100 ,50 ,100
BRVO ,150 ,60 ,50 ,30 65.6(,30–326) ,50 ,100 ,50 ,100
CRVO ,150 ,60 ,50 ,30 985.4(,30–11103) ,50 ,100 ,50 ,100
RRD ,150 ,60 ,50 ,30 701.6(,30–15381) ,50 ,100 ,50 ,100
Values are given as the mean (range) in pg/ml, with the detection limit for each mediator.
doi:10.1371/journal.pone.0008158.t002
Table 3. Concentrations of chemokines in the vitreous cavity.
IL-8 eotaxin MCP-1 MIP-1a MIP-1b RANTES
control 28.9(,30–1538) ,50 100.8(,100–2146.9) ,100 ,100 ,150
DME 258(,30–5522) ,50 1590.1(,100–38394) ,100 ,100 ,150
PDR 394.2(,30–11700) ,50 1665(,100–31099.5) ,100 ,100 ,150
BRVO 473.2(,30–7728) ,50 439.1(,100–2895) ,100 ,100 ,150
CRVO 1027(,30–6822) ,50 2906(195–15045) ,100 ,100 ,150
RRD 285.9(,30–4757) ,50 3944(,100–35811) ,100 ,100 ,150
Values are given as the mean (range) in pg/ml, with the detection limit for each mediator.
doi:10.1371/journal.pone.0008158.t003
Vitreoretinal Immunity
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suggesting intravitreal triamcinolone acetonide as a drug with an
anti-inflammatory property [27–29]. Many studies describing the
analysis of soluble factor profiles in vitreous fluids in a particular
disease have been performed on limited numbers of patients
[10–16]. We herein collected 345 samples from five different
diseases and performed comprehensive analysis of 20 factors for
the first time.
One of our most important finding is that the major three
factors: IL-6, IL-8, and MCP-1 were commonly upregulated in all
the examined diseases (Figure 1) and were correlated with each
other without any independent change (Figure 3). The p-value of
IL-8/MCP-1 in CRVO which was ‘‘not significant’’, (P=0.0899),
but this may be due to the small number of samples (n=13) used.
In general, the three factors (IL-6, IL-8, and MCP-1) were
correlated with each other and increased synchronizing. This high
correlation between the three factors indicates a common pathway
is involved in the formation various vitreoretinal disorders
(Figure 3, 6); IL-6 is a multifunctional cytokine that may indirectly
cause an increase of vascular permeability by inducing the
expression of VEGF [30] or alternatively may directly increase
endothelial cell permeability [31]. IL-8 is produced by endothelial
and glial cells in retinas with ischemic angiogenesis [32]. MCP-1
recruits monocytes, memory T cells, and dendritic cells to sites of
tissue injury and infection [33,34], and its upregulation may
stimulate the infiltration of inflammatory cells into eyes with
vitreoretinal disorders.
Table 4. Concentrations of growth factors in the vitreous
cavity.
EGF VEGF bFGF G-CSF GM-CSF
control ,150 111.0(,150–642.4) ,150 ,150 ,150
DME ,150 175.2(,150–1500.8) ,150 ,150 ,150
PDR ,150 545.7(,150–7900.0) ,150 ,150 ,150
BRVO ,150 167.4(,150–1977.0) ,150 ,150 ,150
CRVO ,150 1635.0(,150–11737) ,150 ,150 ,150
RRD ,150 77.4(,150–712) ,150 ,150 ,150
Values are given as the mean (range) in pg/ml, with the detection limit for each
mediator.
doi:10.1371/journal.pone.0008158.t004
Figure 1. Detection of soluble factors in vitreous fluids from patients. (A) IL-6, (B) IL-8, (C) MCP-1, and (D) VEGF levels in vitreous fluid of
control patients and patients with DME, PDR, BRVO, CRVO, and RRD. The ordinate showed the concentrations of soluble factors in the log scale, bars
represent the mean value of each group. * P,0.05, N.S.: not significant.
doi:10.1371/journal.pone.0008158.g001
Vitreoretinal Immunity
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regulated by nuclear factor-kappa B (NF-kB) [32,35-39]. NF-kB is
found in almost all cell types and is involved in cellular response to
stimuli such as stress, cytokines, free radicals, ultraviolet irradia-
tion, and bacterial or viral antigens, in addition to its central role
in immune response [40]. On the other hand, VEGF is
upregulated by hypoxia through hypoxia-inducible factor 1 alpha
(HIF-1a) [41], which is another transcriptional factor that
regulates genes which response to hypoxia [42]. As proposed in
our study, VEGF may act in an independent pathway to promote
the pathogenesis of all the analyzed vitreoretinal diseases, although
additional studies are required to completely solve this mechanism.
The difference in activation level of a transcription factor may
determine the severity of ischemic, angiogenic, and inflammatory
changes in ocular milieu.
Banerjee et al. [18] have reported that IL-6, IL-8 and MCP-1
were detected in vitreous fluids from patients with PDR, PVR,
idiopathic choroidal neovascular membrane, chronic uveitis, and
lens-induced uveitis (LIU). Furthermore, they reported that a LIU
patient who went through a complicated phacoemulsification
cataract surgery, had the most active disease with higher
concentrations of IL-6 and IL-8 than in chronic uveitis or PDR.
Combined with our results, the data indicate that the major three
factors (IL-6, IL-8 and MCP-1) are critical in multiple vitreoretinal
disorders including uveitis. In their report, however, except of
LIU, the number of samples in each individual disease were less
than ten, which significantly limited the performance of compre-
hensive analysis between several soluble factors.
Because DR (DME and PDR) and RVO (BRVO and CRVO)
are characterized with ischemic retinal angiogenesis, it is
reasonable that VEGF participate in their pathogenesis. Interest-
ingly, the patients with PDR/CRVO showed increase of VEGF,
but not DME/BRVO which had a significant increase of IL-6, IL-
8, and MCP-1 (Figure 1). Nevertheless we do not suggest that
VEGF has no contribution in DME/BRVO since the local levels
of VEGF in the ocular tissues other than the vitreous may still be
elevated. In fact, there are many reports about VEGF as a main
exacerbating factor in DME [43,44].
Another important point concerning DR/RVO, is that VEGF
significantly correlated with the major three factors in PDR but
not in CRVO. The reason for this may be an insufficient reliability
of the correlation analysis due to the small number of samples
from CRVO patients. However, in contrast to PDR, all p-values
(VEGF/IL-6, VEGF/IL-8, VEGF/MCP-1) in CRVO were more
than 0.5 which indicates no correlation (Figure 3 lower three lines,
4B). The lack of correlation may be a result of extremely high
concentrations of VEGF in 3 out of 13 patients (more than
16103 pg/ml) with no consistent high concentrations of the other
Figure 2. IL-6, IL-8 and MCP-1 were mutually increased in all examined vitreoretinal diseases. As an example, Spearman’s correlation
analysis of DME are shown (n=92). In each disease, total of three combinations (IL-6/IL-8, IL-6/MCP-1, and IL-8/MCP-1) were created, and calculated p-
and r-values which indicating the accuracy of correlation.
doi:10.1371/journal.pone.0008158.g002
Figure 3. Summary of correlation analysis. The combination of two factors was calculated for each individual disease and listed in the ordinate.
doi:10.1371/journal.pone.0008158.g003
Vitreoretinal Immunity
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various types of retinal cells including retinal pigment epithelial
cells, pericytes, endothelial cells, Muller cells, and astrocytes
[45,46]. Both ishemia and inflammation can initiate VEGF
production.VEGF production can be induced by other factors
and at the same time initiate a cascade of other factors. Our
hypothesis is that IL-6, IL-8, and MCP-1 in the vitreous cavity
promote vascular permeability that causes DME. Retinal ischemia
leads to an excessive production of VEGF that in turn causes
further progression of DME to PDR. On the other hand, a
substantial amount of VEGF can be initially produced by the
sudden profound retinal ischemia, which in turn induces the major
three factors afterward (Figure 6).
Although RRD causes severe visual impairment, it does not
induce inner retinal ischemia, which makes RRD a distinct disease
from the other examined vitreoretinal diseases. It should be noted
that the major three factors were increased unrelated with VEGF
in RRD patients (Figure 1). Up to this point there have been
reports on significantly high levels of MCP-1 in the vitreous of
PVR (a major complications of RD surgery) patients compared to
samples from patients with a macular hole or idiopathic
premacular fibrosis [14,47–49]. Nakazawa et al. [50] demonstrat-
ed that MCP-1 plays a critical role in mediating RD-induced
photoreceptor apoptosis. Chong et al. [51] showed that IL-6 is a
photoreceptor neuroprotectant in experimental model of RD. It is
possible that factors induced by retinal detachment may have an
additional function other than inflammation. Additional studies
will be required to elucidate this point.
In conclusion, multiplex bead analysis enables a comprehensive
analysis of several soluble factors in samples from patients with
vitreoretinal disorders, using a small volume of vitreous fluid. The
three factors: IL-6, IL-8, and MCP-1 were found to be commonly
upregulated and contribute to the formation of various vitreoret-
inal diseases. VEGF may serve as an additional exacerbating
factor in the progression of PDR, and an independent exacerbat-
ing factor in CRVO. Moreover, IL-6 and MCP-1 were
prominently significant factors in the pathogenesis of RRD
patients. Developing a Luminex base technique for the identifi-
cation of immune mediator profiles in the vitreous opens up new
possibilities of characterizing vitreoretinal diseases and designing
therapies based on these unique correlations.
Materials and Methods
Study Population
Consecutive 339 patients underwent a pars plana vitrectomy
(PPV) at Kyushu University Medical Center (Fukuoka, Japan).
Only patients recruited from September 2005 to February 2007
Figure 4. VEGF independently contribute to the pathogenic process of PDR and CRVO. Spearman’s correlation analysis between VEGF
and IL-6/IL-8/MCP-1 in patients with PDR (n=147) or CRVO (n=13) are shown. In each disease, total of three combinations (VEGF/IL-6, VEGF/IL-8, and
VEGF/MCP-1) were analyzed, and calculated p- and r-values which indicating the accuracy of correlation.
doi:10.1371/journal.pone.0008158.g004
Table 5. Concentrations of IL-6 and VEGF in the vitreous and serum.
vitreous IL-6 serum IL-6 vitreous VEGF serum VEGF
control 13.2(,30–237.1) 139.4(,47.0–1070) 139.6(,150–642.4) 47.8(,156.5–459.4)
PDR 463.3(,30–8630) 97.0(,47.0–875.3) 584(,150–6700) 53.1(,156.5–407.6)
CRVO 1502(,30–11104) 40.6(,47.0–254.0) 2168(,150–11737) 23.8(,156.5–214.4)
Values are given as the mean (range) in pg/ml, with the detection limit for each mediator.
doi:10.1371/journal.pone.0008158.t005
Vitreoretinal Immunity
PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8158were enrolled in this prospective study. Patients profile is shown in
Table 1. DME was defined as DR with swelling of the retina
caused by leaky vessels which can be detected by either
ophthalmoscope/optical coherence tomography (OCT). PDR
was defined as DR with obvious neovasculization with or without
proliferative tissue. Macular edema complicated by BRVO or
CRVO was considered as the decisive indication for PPV. As a
control, we selected total 81 patients with either MH or ERM that
were free of major pathogenic intraocular changes.
Vitreous Fluid and Serum Preparation
Under either general or topical anesthesia, undiluted vitreous
fluid (200–900 ml) was first collectedby 3-port pars plana vitrectomy
using a 20- or 23-gauge vitreous cutter with a 5 mL-syringe,
followed by irrigation from infusion port. Samples were immedi-
ately placed in sterile 1.5 ml polypropylene tubes on ice and stored
at 270uC until used. Samples with obvious bleeding were excluded.
Serum samples were also obtained from patients. The samples
were aliquoted and stored at 270uC until use. However, not all of
them were stored in a well condition. We thus need to reduce the
numbers (control: n=83R53, PDR: n=147R66, CRVO:
n=13R8), but we could measure the serum concentration of
IL-6 and VEGF by standard ELISA technique. For comparison
between serum and vitreous, vitreous IL-6/VEGF concentrations
of corresponding individuals were extracted from previous
measurement (shown in Figure 1), and then reorganized as
Figure 5 and Table 5.
The research followed the tenets of the Declaration of Helsinki
and the internal Ethics Committees of Kyushu University which
approved all the protocols. Written informed consent was obtained
from all enrolled patients.
Protein Analysis and Antibodies
To minimize interfering of fibers and gels in the samples,
vitreous samples were diluted 1:10 in PBS. The concentration of
cytokines, chemokines, and growth factors in vitreous specimens
were measured using a microbead-based ELISA system [17].
Briefly, in this technique, microbeads with defined spectral
properties are conjugated to protein-specific antibodies and added
along with samples (samples include protein standards in a known
concentration, control samples, and test samples) into wells of a
filter-bottom microplate. This mixure is incubaed for 2 hrs to
allow antibody and protein binding. After washing the beads,
protein-specific biotinylated detector antibodies are added and
incubated with the beads for 1 hr. Then after removal of excess
biotinylated antibodies, streptavidin conjugated to a fluorescent
protein: R-Phycoerythrin (Streptavidin-RPE), is added and
incubated for 30 min. After washing of unbound Streptavidin-
RPE, the beads are analyzed with the LuminexH 100 (Luminex,
Figure 5. Serum IL-6 and VEGF concentrations are not significantly related with vitreous concentrations. Shown are comparison of (A)
IL-6, and (B) VEGF levels in vitreous and in serum of patients with control (n=53), PDR (n=66) and CRVO (n=8). The ordinate showed the
concentrations of soluble factors in the log scale, bars represent the mean value of each group. Bars represent the mean value of each group.
* P,0.01, N.S.: not significant.
doi:10.1371/journal.pone.0008158.g005
Figure 6. Possible contribution of major four factors: IL-6, IL-8,
MCP-1 and VEGF in vitreoretinal diseases. A scheme illustrates
the relations between the different mediators in samples from the
different vitreoretinal diseases: IL-6, IL-8, and MCP-1 in the vitreous
cavity can increase vascular permeability that causes DME, but an
additional retinal ischemia led to increased VEGF production that play
an important role in the progression of DME to PDR. At the same time,
high VEGF levels may be initially produced by the sudden profound
retinal injury, and then induced major three factors, frequently resulted
in rubeosis iriditis.
doi:10.1371/journal.pone.0008158.g006
Vitreoretinal Immunity
PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8158Austin, TX, USA). By monitoring the spectral properties of the
beads and the amount of associated R-Phycoerythrin (RPE)
fluorescence, the concentration of one or more proteins can be
determined. The following antibodies were used: Human
Cytokine Ten-Plex Antibody Bead Kit, Cat. No. LHC0001,
Human IL-17 Antibody Bead Kit, Cat. No. LHC0171, Human
Chemokine Five-Plex Antibody Bead Kit, Cat. No. LHC0005,
Human Growth Factor Four-Plex Antibody Bead Kit, Cat.
No. LHC0004; BioSource International, Camarillo USA). Serum
samples were diluted 1:5 in PBS, then IL-6 and VEGF
concentrations were measured by ELISA development kits
(Human IL-6 DuoSet and Human VEGF Duoset, R&D systems,
Minneapolis, MN) according to the manufacturer’s directions.
Statistical Analysis
All analyses were performed with GraphPad Prism 4.0c
(GraphPad Software Inc., San Diego, CA). A non-parametric
Mann-Whitney U-test and Kruskal-Wallis test for non-normal
distribution were used to analyze immune mediators and patient
age variance, respectively. Correlation studies were performed by
Spearman’s non-parametric test. P-values less than 0.05 were
considered as significantly different.
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